Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Globus MedicalGMED +1.57%95 Peter Lynch Fair Value is $91.32 as of Aug. 09, 2026, which is 3597% above its 10-year median of 2.47. GuruFocus rates GMED with a GF Score™ of 95/100 and a GF Value™ of $97.18 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 152 Medical Devices & Instruments companies, Globus Medical ranks better than 73.68% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Globus Medical's PEG is 1. Globus Medical's 5-Year TTM EBITDA Growth Rate is 19.18.
Globus Medical's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $4.76. Therefore, the Peter Lynch Fair Value for today is $91.32.
As of today (2026-08-09), Globus Medical's share price is $82.35. Globus Medical's Peter Lynch fair value is $91.32. Therefore, Globus Medical's Price to Peter Lynch Fair Value Ratio for today is 0.90.
The historical rank and industry rank for Globus Medical's Peter Lynch Fair Value or its related term are showing as below:
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Globus Medical was 6.81. The lowest was 0.95. And the median was 2.47.
GMED's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.49 * Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Globus Medical (NYSE:GMED) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 19.18 instead of 15 in this case.
Globus Medical's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
82.35
/
91.32
=
0.90
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Globus Medical Peter Lynch Fair Value Related Terms
Globus Medical Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Globus Medical's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GMED vs PODD, BRKR, GKOS: Peter Lynch Fair Value Comparison
For the Medical Devices subindustry, Globus Medical's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Globus Medical Price-to-Peter-Lynch-Fair-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Globus Medical's Price-to-Peter-Lynch-Fair-Value falls into.
Globus Medical's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.76.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of $91.32 mean?
Globus Medical (GMED) has a Peter Lynch Fair Value of $91.32 as of Aug. 09, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Globus Medical and its competitors. This is 3597% above median its historical median of 2.47. Over the past decade, Globus Medical's Peter Lynch Fair Value has ranged from 0.95 to 6.81. According to the industry distribution chart, Globus Medical ranks #40 out of 152 companies in the Medical Devices & Instruments industry, placing it in the top 26.3%.
Is Globus Medical's Peter Lynch Fair Value too high?
Globus Medical's current Peter Lynch Fair Value of $91.32 is 3597% above median its 10-year median of 2.47. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 6.81. The Medical Devices & Instruments industry median Peter Lynch Fair Value is 1.49. Globus Medical's value of $91.32 is 6028.9% above this industry median. Based on the distribution chart, Globus Medical ranks #40 out of 152 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Globus Medical has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's Peter Lynch Fair Value compare to PODD and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Globus Medical ranks #40 out of 152 companies for Peter Lynch Fair Value. This puts Globus Medical in the upper half of its industry. The industry median Peter Lynch Fair Value is 1.49. Globus Medical's value of $91.32 is 6028.9% above this benchmark. Historically, Globus Medical's own Peter Lynch Fair Value has ranged from 0.95 to 6.81 over the past decade. While the company's 10-year median is 2.47 vs. the industry median of 1.49, Globus Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Devices & Instruments company?
The median Peter Lynch Fair Value among Medical Devices & Instruments companies is 1.49, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Globus Medical's current Peter Lynch Fair Value of $91.32 is 6028.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Globus Medical and its competitors. For the Medical Devices & Instruments industry, the median Peter Lynch Fair Value is 1.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Globus Medical's current Peter Lynch Fair Value is $91.32, which is 3597% above median its own 10-year median of 2.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (GMED) is currently considered Modestly Undervalued. The stock's GF Value™ is $97.18, compared to a current price of $82.35 — trading 15.3% below its estimated fair value. The current Peter Lynch Fair Value is $91.32, which is 3597% above median its 10-year median of 2.47 and 6028.9% above the Medical Devices & Instruments industry median of 1.49. Globus Medical's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Globus Medical (GMED), the current Peter Lynch Fair Value is $91.32 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Globus Medical (GMED) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of $82.35 is trading 15.3% below its estimated GF Value™ of $97.18.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for GMED:
Peter Lynch Fair Value: $91.32 (3597% above median its 10-year median of 2.47)
GF Value™: $97.18 vs. price of $82.35 (15.3% below fair value)
Industry Position: 6028.9% above the Medical Devices & Instruments median (#40 of 152)
No single metric tells the full story. See the GMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
95GF Score
Get the complete analysis for GMED
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GMED has been successfully added to your 
